Liraglutide drug associated with lower risk of cardiovascular events

Real world data from a large Nordic study shows that use of liraglutide, a drug for type 2 diabetes, is associated with a lower risk of myocardial infarction, stroke or cardiovascular death. The study, led by researchers from Karolinska Institutet in Swe https://www.news-medical.net/news/20181206/Liraglutide-drug-associated-with-lower-risk-of-cardiovascular-events.aspx